Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer disease

Debomoy Lahiri, George M. Alley, David Tweedie, Demao Chen, Nigel H. Greig

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

One of the main hallmarks of Alzheimer's disease (AD) is the brain deposition of senile plaques made up of toxic amyloid Β-peptide (AΒ), which is derived from a larger protein called the Β-amyloid precursor protein (APP). Both APP processing and cholinesterase activity are affected in the AD brain, but, yet, cholinesterase inhibitors (ChEI) remain the primary Food and Drug Administration approved drugs for AD within the United States. Herein, we evaluated the effects of two clinically relevant drugs on the APP pathway, which is presumably involved in AD pathogenesis. Specifically, we compared the actions of the classical ChEI physostigmine (PHY) and its analog phenserine (PHE) on neuronal cell viability, on IC50 and on levels of different amyloid proteins. Interestingly, these drugs share the same chemical backbone, inhibit acetylcholinesterase with similar potency, but differentially affect APP processing. PHE treatment decreased levels of APPin the human neuroblastoma cells (p ≤ 0.009) whereas PHYshowed a similar but less-pronounced trend, which did not attain statistical significance. PHE treatment significantly decreased levels of AΒ in human neuroblastoma cells (p ≤ 0.02) whereas PHY showed no significant change under the same conditions. The divergent actions of these two structurally related drugs on the amyloid pathway indicate that the mechanisms underpinning the cholinergic and the amyloid-lowering properties for this class of drugs are independent of each other.

Original languageEnglish
Pages (from-to)157-168
Number of pages12
JournalNeuroMolecular Medicine
Volume9
Issue number2
DOIs
StatePublished - Jun 2007

Fingerprint

Carbamates
Amyloid beta-Peptides
Cholinesterase Inhibitors
Amyloid beta-Protein Precursor
Alzheimer Disease
Amyloid
Physostigmine
Pharmaceutical Preparations
Neuroblastoma
Amyloidogenic Proteins
Poisons
Cholinesterases
Amyloid Plaques
Brain
United States Food and Drug Administration
Acetylcholinesterase
Cholinergic Agents
Inhibitory Concentration 50
Cell Survival
phenserine

Keywords

  • β-protein
  • Acetylcholine
  • Aging
  • Anticholinesterase
  • Cell culture
  • CNS
  • Dementia
  • Drugs
  • ELISA
  • Neuron
  • Phenylcarbamate

ASJC Scopus subject areas

  • Neuroscience(all)
  • Genetics
  • Cell Biology

Cite this

Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer disease. / Lahiri, Debomoy; Alley, George M.; Tweedie, David; Chen, Demao; Greig, Nigel H.

In: NeuroMolecular Medicine, Vol. 9, No. 2, 06.2007, p. 157-168.

Research output: Contribution to journalArticle

@article{60f25f1eead24783bd78f8e5ac6fd223,
title = "Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer disease",
abstract = "One of the main hallmarks of Alzheimer's disease (AD) is the brain deposition of senile plaques made up of toxic amyloid Β-peptide (AΒ), which is derived from a larger protein called the Β-amyloid precursor protein (APP). Both APP processing and cholinesterase activity are affected in the AD brain, but, yet, cholinesterase inhibitors (ChEI) remain the primary Food and Drug Administration approved drugs for AD within the United States. Herein, we evaluated the effects of two clinically relevant drugs on the APP pathway, which is presumably involved in AD pathogenesis. Specifically, we compared the actions of the classical ChEI physostigmine (PHY) and its analog phenserine (PHE) on neuronal cell viability, on IC50 and on levels of different amyloid proteins. Interestingly, these drugs share the same chemical backbone, inhibit acetylcholinesterase with similar potency, but differentially affect APP processing. PHE treatment decreased levels of APPin the human neuroblastoma cells (p ≤ 0.009) whereas PHYshowed a similar but less-pronounced trend, which did not attain statistical significance. PHE treatment significantly decreased levels of AΒ in human neuroblastoma cells (p ≤ 0.02) whereas PHY showed no significant change under the same conditions. The divergent actions of these two structurally related drugs on the amyloid pathway indicate that the mechanisms underpinning the cholinergic and the amyloid-lowering properties for this class of drugs are independent of each other.",
keywords = "β-protein, Acetylcholine, Aging, Anticholinesterase, Cell culture, CNS, Dementia, Drugs, ELISA, Neuron, Phenylcarbamate",
author = "Debomoy Lahiri and Alley, {George M.} and David Tweedie and Demao Chen and Greig, {Nigel H.}",
year = "2007",
month = "6",
doi = "10.1007/s12017-007-0005-4",
language = "English",
volume = "9",
pages = "157--168",
journal = "NeuroMolecular Medicine",
issn = "1535-1084",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer disease

AU - Lahiri, Debomoy

AU - Alley, George M.

AU - Tweedie, David

AU - Chen, Demao

AU - Greig, Nigel H.

PY - 2007/6

Y1 - 2007/6

N2 - One of the main hallmarks of Alzheimer's disease (AD) is the brain deposition of senile plaques made up of toxic amyloid Β-peptide (AΒ), which is derived from a larger protein called the Β-amyloid precursor protein (APP). Both APP processing and cholinesterase activity are affected in the AD brain, but, yet, cholinesterase inhibitors (ChEI) remain the primary Food and Drug Administration approved drugs for AD within the United States. Herein, we evaluated the effects of two clinically relevant drugs on the APP pathway, which is presumably involved in AD pathogenesis. Specifically, we compared the actions of the classical ChEI physostigmine (PHY) and its analog phenserine (PHE) on neuronal cell viability, on IC50 and on levels of different amyloid proteins. Interestingly, these drugs share the same chemical backbone, inhibit acetylcholinesterase with similar potency, but differentially affect APP processing. PHE treatment decreased levels of APPin the human neuroblastoma cells (p ≤ 0.009) whereas PHYshowed a similar but less-pronounced trend, which did not attain statistical significance. PHE treatment significantly decreased levels of AΒ in human neuroblastoma cells (p ≤ 0.02) whereas PHY showed no significant change under the same conditions. The divergent actions of these two structurally related drugs on the amyloid pathway indicate that the mechanisms underpinning the cholinergic and the amyloid-lowering properties for this class of drugs are independent of each other.

AB - One of the main hallmarks of Alzheimer's disease (AD) is the brain deposition of senile plaques made up of toxic amyloid Β-peptide (AΒ), which is derived from a larger protein called the Β-amyloid precursor protein (APP). Both APP processing and cholinesterase activity are affected in the AD brain, but, yet, cholinesterase inhibitors (ChEI) remain the primary Food and Drug Administration approved drugs for AD within the United States. Herein, we evaluated the effects of two clinically relevant drugs on the APP pathway, which is presumably involved in AD pathogenesis. Specifically, we compared the actions of the classical ChEI physostigmine (PHY) and its analog phenserine (PHE) on neuronal cell viability, on IC50 and on levels of different amyloid proteins. Interestingly, these drugs share the same chemical backbone, inhibit acetylcholinesterase with similar potency, but differentially affect APP processing. PHE treatment decreased levels of APPin the human neuroblastoma cells (p ≤ 0.009) whereas PHYshowed a similar but less-pronounced trend, which did not attain statistical significance. PHE treatment significantly decreased levels of AΒ in human neuroblastoma cells (p ≤ 0.02) whereas PHY showed no significant change under the same conditions. The divergent actions of these two structurally related drugs on the amyloid pathway indicate that the mechanisms underpinning the cholinergic and the amyloid-lowering properties for this class of drugs are independent of each other.

KW - β-protein

KW - Acetylcholine

KW - Aging

KW - Anticholinesterase

KW - Cell culture

KW - CNS

KW - Dementia

KW - Drugs

KW - ELISA

KW - Neuron

KW - Phenylcarbamate

UR - http://www.scopus.com/inward/record.url?scp=34447567415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447567415&partnerID=8YFLogxK

U2 - 10.1007/s12017-007-0005-4

DO - 10.1007/s12017-007-0005-4

M3 - Article

C2 - 17627035

AN - SCOPUS:34447567415

VL - 9

SP - 157

EP - 168

JO - NeuroMolecular Medicine

JF - NeuroMolecular Medicine

SN - 1535-1084

IS - 2

ER -